Australia Issues Mental Health Alert for Weight-Loss Medications Like Ozempic

The Therapeutic Goods Administration (TGA) has issued new safety alerts concerning weight loss and diabetes medications. These warnings address potential mental health risks and reduced effectiveness of oral contraceptives when using drugs like Mounjaro.

Mental Health Alert Issued for Weight-Loss Medications

The medicines regulator has introduced a pair of new safety alerts regarding mental well-being and contraception for individuals using prominent diabetes and weight management medications.

The Therapeutic Goods Administration (TGA) has stated that, due to reports of suicidal behavior and ideation associated with these relatively new GLP-1 receptor agonists, medical professionals should closely monitor patients for the development or worsening of depression, suicidal thoughts or actions, and any unusual shifts in mood or behavior.

This caution regarding the possible risk of suicidal thoughts is applicable across the GLP-1 RA class of drugs, including Ozempic, Wegovy, Saxenda, Trulicity, and Mounjaro. Health tracking apps like Shotlee can help monitor any changes in mood or behavior in conjunction with medical advice.

Contraception Warning Issued Separately

The TGA has also released a distinct alert concerning Mounjaro and its interaction with contraception.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Following an investigation into the potential for reduced efficacy of oral contraceptives when initiating or increasing the dosage of Mounjaro, the TGA indicated that it could not exclude a correlation.

As a precautionary measure, product warnings for Mounjaro have been revised to incorporate additional guidance for patients using oral contraceptives. It is advised to switch to a non-oral contraceptive method or incorporate a barrier method for four weeks after initiating the medication and for four weeks following each dosage increase.

Furthermore, it is advised that no medication within the GLP-1 RA class should be administered during pregnancy.

Source Information

Originally published by The Guardian.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read

Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: medications

All medications articles →

Wellness & Health

New Yorkers Are Ordering Peptides Like Takeout – And California Trim Clinic Is Behind It

New York City is experiencing a surge in peptide therapy requests via telehealth platforms. This article explores the most popular compounds, safety protocols, and how to track results effectively.

8 min read

Pharmaceutical Industry News

Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics

Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.

8 min read

More in Health

Health

Natural Alternatives to Ozempic? 6 GLP-1 Rich Foods That Mimic the Effects

Weight loss medications such as Ozempic and Wegovy function by artificially elevating glucagon-like peptide 1 (GLP-1), a naturally occurring hormone that combats obesity and diabetes. Research indicates that certain foods can boost GLP-1 secretion, offering similar benefits without injections. These foods not only increase GLP-1 but also mimic its effects, aiding in weight management and overall health.

6 min read

Health

Weight Loss Meds Linked to Another Debilitating Adverse Effect

Weight loss medications, specifically GLP-1 receptor agonists, have been associated with an increased risk of chronic cough in individuals with type 2 diabetes. A recent study compared patients taking GLP-1s with those on other diabetes treatments, revealing a notable link between the drugs and persistent coughing.

5 min read

Health

Understanding GLP-1 Drugs: Weight Loss, Diabetes, and Side Effects

GLP-1 drugs are prescription medicines utilized to treat type 2 diabetes and aid weight loss under medical supervision. These medications work by imitating hormones responsible for controlling blood sugar and appetite. It is important to obtain them from regulated sources.

1 min read